KDMN - FDA accepts Kadmon belumosudil application for graft-versus-host disease shares up 4%
Under Priority Review status, the FDA accepts Kadmon Holdings' (KDMN) marketing application seeking approval of belumosudil, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of patients with chronic graft-versus-host disease.The agency's action date is May 30, 2021.Shares up 4% premarket on light volume.
For further details see:
FDA accepts Kadmon belumosudil application for graft-versus-host disease, shares up 4%